FI104363B - Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon - Google Patents
Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon Download PDFInfo
- Publication number
- FI104363B FI104363B FI972121A FI972121A FI104363B FI 104363 B FI104363 B FI 104363B FI 972121 A FI972121 A FI 972121A FI 972121 A FI972121 A FI 972121A FI 104363 B FI104363 B FI 104363B
- Authority
- FI
- Finland
- Prior art keywords
- cyclosporins
- interferons
- rapamycin
- peptides
- amino acid
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 21
- 108010050904 Interferons Proteins 0.000 title claims description 21
- 239000003018 immunosuppressive agent Substances 0.000 title abstract description 14
- 229960003444 immunosuppressant agent Drugs 0.000 title abstract description 12
- 229940079322 interferon Drugs 0.000 title description 5
- 239000000654 additive Substances 0.000 title description 3
- 230000006872 improvement Effects 0.000 title description 3
- 230000000996 additive effect Effects 0.000 title description 2
- 230000000144 pharmacologic effect Effects 0.000 title description 2
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 55
- 108010036941 Cyclosporins Proteins 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract description 23
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 23
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 23
- 229960002930 sirolimus Drugs 0.000 claims abstract description 23
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 210000000056 organ Anatomy 0.000 claims abstract description 3
- 238000002054 transplantation Methods 0.000 claims abstract 2
- 229940047124 interferons Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000002244 anti-lymphoproliferative effect Effects 0.000 abstract description 10
- 230000027455 binding Effects 0.000 abstract description 9
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 33
- 108010036949 Cyclosporine Proteins 0.000 description 33
- 229960001265 ciclosporin Drugs 0.000 description 32
- 229930105110 Cyclosporin A Natural products 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 230000002519 immonomodulatory effect Effects 0.000 description 13
- 108010014726 Interferon Type I Proteins 0.000 description 12
- 102000002227 Interferon Type I Human genes 0.000 description 12
- 230000001589 lymphoproliferative effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 11
- 230000001028 anti-proliverative effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 108010086408 albebetin Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 3
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000017830 lymphoblastoma Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000000521 Immunophilins Human genes 0.000 description 2
- 108010016648 Immunophilins Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 2
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 210000002925 A-like Anatomy 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091011114 FK506 binding proteins Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 1
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 102100034400 Nuclear factor of activated T-cells, cytoplasmic 2 Human genes 0.000 description 1
- 101710151538 Nuclear factor of activated T-cells, cytoplasmic 2 Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000006534 Zavyalov synthesis reaction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (5)
1. Vilken som heist blandning som innehäller immunsuppressorer cyklosporinema, FK506 eller rapamycin, och naturliga eller rekombinanta interferoner av typen I, in-terferonerna α, β,ω,τ,eller bioaktiva peptider motsvarande deras struktur, eller re- kombinantproteiner innehällande en eller flera sagda peptiders struktur, vilken blandning är avsedd att ömsesidigt oka sagda immunsuppressorernas och interfero-nernas aktivitet och/eller minska den terapeutiska dosen av dessa, varvid läkemed-lens icke-önskade biverkningar undviks vid transplantation av organ eller vävnader eller behandling av cancer, säsom lymfom,, leukemier, myelom, adenokarcinom; au-toimmuna och kroniska inflammationssjukdomar säsom reumatoid artrit, myasthenia gravis, lupus erythematosus, uveit, hyperproliferativa sjukdomar säsom psoriasis vulgaris. vid vilka FK506 eller rapamycin och interferoner används.
2. Blandningar enligt patentkrav 1 innehällande immunsuppressorer cyklosporinema, FK506 eller rapamycin tillsammans med en eller flera peptider innehällande ätminsto-ne 5 identiska aminosyrarester ur följande tabell. L TEKKY S P RRRRHRR QDND DD MLMN NL I S S S K K G H E A E A G I där varje aminosyra i den översta sekvensen kan ersättas med vilken som heist ne-danför den belägen aminosyrarest.
3. Läkemedelsblandningar enligt krav 1 innehällande immunsuppressorer cyklospo-rinerna..FK506 eller rapamycin och rekombinanta polypeptider innehällande en eller flera polypeptidsekvenser enligt krav 2.
4. Blandningar enligt kraven 1 och 2 innehällande immunsuppressorer syklospori-nerna, FK506 eller rapamycin och bioaktiva peptider eller interferoner, i vilka sagda aktiva peptider eller interferoner är genetiskt eller kemiskt modifierade, eller genetiskt, 17 104363 kemiskt eller fysikaliskt bundna till lägmolekulära eller högmolekulära ämnen med avsikt att röka peptidernas eller interferonernas stabilitet under fysiologiska förhäl-landen och/eller med avsikt att reglera peptidernas biotillgänlighet.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI972121A FI104363B (sv) | 1997-05-19 | 1997-05-19 | Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon |
| PCT/FI1998/000418 WO1998052594A1 (en) | 1997-05-19 | 1998-05-18 | Compositions for enhancing immunosuppressants' pharmaceutical activities |
| AT98921528T ATE234624T1 (de) | 1997-05-19 | 1998-05-18 | Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva |
| JP55000998A JP2001526675A (ja) | 1997-05-19 | 1998-05-18 | 免疫抑制剤の薬剤活性を向上させる組成物 |
| DE69812347T DE69812347T9 (de) | 1997-05-19 | 1998-05-18 | Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva |
| AU74352/98A AU7435298A (en) | 1997-05-19 | 1998-05-18 | Compositions for enhancing immunosuppressants' pharmaceutical acti vities |
| EP98921528A EP0981359B1 (en) | 1997-05-19 | 1998-05-18 | Compositions for enhancing immunosuppressants' pharmacological activities |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI972121 | 1997-05-19 | ||
| FI972121A FI104363B (sv) | 1997-05-19 | 1997-05-19 | Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI972121A0 FI972121A0 (fi) | 1997-05-19 |
| FI972121L FI972121L (sv) | 1998-11-20 |
| FI104363B true FI104363B (sv) | 2000-01-14 |
Family
ID=8548873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI972121A FI104363B (sv) | 1997-05-19 | 1997-05-19 | Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0981359B1 (sv) |
| JP (1) | JP2001526675A (sv) |
| AT (1) | ATE234624T1 (sv) |
| AU (1) | AU7435298A (sv) |
| DE (1) | DE69812347T9 (sv) |
| FI (1) | FI104363B (sv) |
| WO (1) | WO1998052594A1 (sv) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20021774L (sv) * | 2002-10-07 | 2004-04-08 | Dmitry Aleksandrovich Dolgikh | Peptider och rekombinanta proteiner som imiterar antivirala och antiproliferativa aktiviteter av interferoner |
| JP2006517969A (ja) * | 2003-02-14 | 2006-08-03 | コンビナトアールエックス インコーポレーティッド | 免疫炎症性障害の治療のための組み合わせ療法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009806A2 (en) * | 1989-03-02 | 1990-09-07 | University Of Florida | Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses |
| CN1090510A (zh) * | 1992-10-30 | 1994-08-10 | 佛罗里达大学 | 干扰素-τ组成物及其用途 |
| FR2706772A1 (en) * | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
-
1997
- 1997-05-19 FI FI972121A patent/FI104363B/sv not_active IP Right Cessation
-
1998
- 1998-05-18 EP EP98921528A patent/EP0981359B1/en not_active Expired - Lifetime
- 1998-05-18 DE DE69812347T patent/DE69812347T9/de not_active Expired - Fee Related
- 1998-05-18 WO PCT/FI1998/000418 patent/WO1998052594A1/en not_active Ceased
- 1998-05-18 JP JP55000998A patent/JP2001526675A/ja not_active Ceased
- 1998-05-18 AT AT98921528T patent/ATE234624T1/de not_active IP Right Cessation
- 1998-05-18 AU AU74352/98A patent/AU7435298A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| FI972121L (sv) | 1998-11-20 |
| ATE234624T1 (de) | 2003-04-15 |
| FI972121A0 (fi) | 1997-05-19 |
| EP0981359A1 (en) | 2000-03-01 |
| DE69812347T2 (de) | 2004-02-19 |
| WO1998052594A1 (en) | 1998-11-26 |
| EP0981359B1 (en) | 2003-03-19 |
| DE69812347D1 (de) | 2003-04-24 |
| AU7435298A (en) | 1998-12-11 |
| DE69812347T9 (de) | 2004-09-23 |
| JP2001526675A (ja) | 2001-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI510622B (zh) | 用於治療及／或預防自體免疫疾病及用於調節性ｔ細胞形成之藥劑 | |
| Burman et al. | Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon | |
| US5780021A (en) | Method for treating type 1 diabetes using α-interferon and/or β-i | |
| AU688214B2 (en) | Method for treatment of autoimmune diseases using interferon-TAU | |
| CZ55194A3 (en) | Preparation for treating mammals infected by hepatitis c virus | |
| JPH05501866A (ja) | 自己免疫性ブドウ膜網膜炎の治療予防薬 | |
| AU2187599A (en) | Histone containing composition to treat rheumatoid arthritis | |
| FI104363B (sv) | Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| CA2185794C (en) | Agent for relieving side effects caused by immunosuppressants | |
| JPH10167982A (ja) | 劇症肝炎疾患治療剤 | |
| KR20060126631A (ko) | 인터페론-타우의 의약으로서의 용도 | |
| US5317012A (en) | Human growth hormone induced improvement in depressed T4/T8 ratio | |
| US20030186839A1 (en) | Medicinal compositions | |
| KR20050054119A (ko) | 잔소리졸을 함유하는 면역억제제 | |
| AU2004200074C1 (en) | Agent for relieving side effects caused by immunosuppressants | |
| KR100439928B1 (ko) | 면역억제제로서의아스피로클로라인또는그의유도체의용도 | |
| JPH11507023A (ja) | 血清免疫調節ポリペプチドおよびそれらの使用 | |
| JPH07188049A (ja) | 代謝不全肝疾患の患者の治療のための方法および組成物 | |
| AU751199B2 (en) | Composition and method of treating hepatitis B | |
| COOK | The Mechanism of Induction of Interferon Gamma Synthesis by Human Thymocytes | |
| Stebbing | Proteins as Therapeutics: Potential and Problems | |
| Combates | Effects of cyclosporin and rapamycin on the in vitro activation of human CD8+ lymphocytes in comparison with peripheral blood mononuclear cells | |
| Sze | Chemical and biological characterizations of the edible mushroom Volvariella volvacea lectins | |
| Streams et al. | INFO: Side Effects of Interferon Alpha in Viral Hepatitis Rate this topic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |